Publikationen

Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stoger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R. BREAST CARE. 2021; https://doi.org/10.1159/000516157

View this publication in the PUBMED database

Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?

Rinnerthaler, G; Müller, V; Balic, M; Zaman, K; Dieci, MV. Breast Care (Basel). 2021 Apr;16(2):188-191. doi: 10.1159/000515746. Epub 2021 Mar 26.

View this publication in the PUBMED database

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Greil, R; Tedeschi, A; Moreno, C; Anz, B; Larratt, L; Simkovic, M; Gill, D; Gribben, JG; Flinn, IW; Wang, ZY; Cheung, LWK; Nguyen, AN; Zhou, C; Sty-les, L; Demirkan, F. Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20.

View this publication in the PUBMED database

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).

Hecht, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY. J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.

View this publication in the PUBMED database

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.

Bernard, S; Ghesquieres, H; Casasnovas, RO; Griolet, S; da Silva, MG; Feugier, P; Morschhauser, F; Trotman, J; Renaud, L; Greil, R; Garcia-Sancho, AM; Grosicki, S; van Eygen, K; Copie-Bergman, C; Haioun, C; Thieblemont, C. Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766.

View this publication in the PUBMED database

The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.

Leeksma AC, Derks IAM, Kasem MH, Kilic E, de Klein A, Jager MJ, van de Loosdrecht AA, Jansen JH, Navrkalova V, Faber LM, Zaborsky N, Egle A, Zenz T, Pospisilova S, Abdel-Wahab O, Kater AP, Eldering E. Front Oncol. 2021 Jan 29;10:609409. doi: 10.3389/fonc.2020.609409. eCollection 2020.

View this publication in the PUBMED database

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature.

Heregger, R; Huemer, F; Hutarew, G; Hecht, S; Cheveresan, L; Kotzot, D; Schamschula, E; Rinnerthaler, G; Melchardt, T; Weiss, L; Greil, R. ESMO Open. 2021 Aug;6(4):100233. doi: 10.1016/j.esmoop.2021.100233. Epub 2021 Aug 7.

View this publication in the PUBMED database

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.

Keil, F; Hartl, M; Altorjai, G; Berghold, A; Riedl, R; Pecherstorfer, M; Mayrbäurl, B; De Vries, A; Schuster, J; Hackl, J; Füreder, T; Melchardt, T; Burian, M; Greil, R. Eur J Cancer. 2021 Jul;151:201-210. doi: 10.1016/j.ejca.2021.03.051. Epub 2021 May 19.

View this publication in the PUBMED database

Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia af-ter Chimeric Antigen Receptor T-Cell Therapy.

Kiem, D; Leisch, M; Neureiter, D; Haslauer, T; Egle, A; Melchardt, T; Topp, MS; Greil, R. Int J Mol Sci. 2021 May 21;22(11):5449. doi: 10.3390/ijms22115449.

View this publication in the PUBMED database

Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.

Kocher, F; Tymoszuk, P; Amann, A; Sprung, S; Salcher, S; Daum, S; Haybaeck, J; Rinnerthaler, G; Huemer, F; Kauffmann-Guerrero, D; Tufman, A; Seeber, A; Wolf, D; Pircher, A. Lung Cancer. 2021 Sep;159:84-95. doi: 10.1016/j.lungcan.2021.06.020. Epub 2021 Jul 16.

View this publication in the PUBMED database
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.